These data strongly suggest that MAPKi-resistance development in a subset of melanomas correlates with a reduction of p73 mRNA expression, which is most likely mediated by the lower expression of the intrinsically highly expressed N-terminal TAp73 and C-terminal p73α isoform. Here, TP73 is linked to melanoma.